Strategic funding PathMaker has secured early-stage funding and government awards (CDMRP/ALSRP, START Stage 2, NIH grant, MDA MVP investment) indicating credibility and potential for partnerships or co-development opportunities with larger players seeking innovative neuromodulation solutions.

Non invasive niche The company's focus on non-invasive neuromodulation for ALS and serious neurological disorders presents a compelling value proposition for hospitals, research centers, and payers seeking treatment options with reduced surgical risk and faster patient onboarding.

Strategic leadership Recent leadership appointments including a new Board Chair and a new Board Director signal governance maturation and strategic pivot potential, which can be leveraged to advocate for joint ventures, advisory collaborations, or sponsored studies with larger medical tech firms.

Clinical readiness As a clinical-stage company with active pilot/clinical trial funding, there are near-term opportunities for contract research, site partnerships, investigator collaborations, and early access programs with ALS centers and neurology research networks.

Ecosystem fit With a traction story tied to MDA MVP, CERF prize, NIH grants, and defense-supported ALS funding, PathMaker aligns with large medtech players and investors looking to expand neuromodulation portfolios, enabling partnerships for co-development, manufacturing, or distribution agreements.